Last $5.11 USD
Change Today +0.16 / 3.23%
Volume 61.7K
SVA On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

sinovac biotech ltd (SVA) Snapshot

Open
$4.93
Previous Close
$4.95
Day High
$5.11
Day Low
$4.93
52 Week High
03/21/14 - $8.14
52 Week Low
09/30/14 - $4.51
Market Cap
281.5M
Average Volume 10 Days
118.0K
EPS TTM
$0.06
Shares Outstanding
55.1M
EX-Date
--
P/E TM
83.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for SINOVAC BIOTECH LTD (SVA)

sinovac biotech ltd (SVA) Related Businessweek News

No Related Businessweek News Found

sinovac biotech ltd (SVA) Details

Sinovac Biotech Ltd., a biopharmaceutical company, is engaged in the research, development, manufacture, and commercialization of vaccines for hepatitis A, hepatitis B, and influenza viruses in the People's Republic of China. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and RabEnd, an animal rabies vaccine. The company has also completed a phase I clinical trial of a SARS vaccine, as well as develops the EV71 vaccine, which has completed phase III clinical trial. Further, it develops a pipeline of vaccine candidates in the clinical and pre-clinical development phases, including human vaccines for pneumococcal, rabies, varicella, and rubella that are in pre-clinical stage. The company has a collaboration agreement with Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to virus strain production for vaccines, including the H5N1 influenza virus strain. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.

715 Employees
Last Reported Date: 04/16/14
Founded in 1999

sinovac biotech ltd (SVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sinovac biotech ltd (SVA) Key Developments

Sinovac Biotech Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Sinovac Biotech reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, net income attributable to common stockholders of the company was $89,000, or $0.00 per basic and diluted share, compared to $2.3 million, or $0.04 per basic and diluted share, in third quarter 2013. Quarterly sales were $17.1 million, a decrease of 22.3% from $22.1 million in the prior year period, which includes recognition of a special order of pandemic influenza vaccine revenue of $3.6 million. Excluding the impact from this special order, third quarter sales of regular vaccine products decreased 7.4% from the prior year period. Operating income was $894,000 compared to $3.00 million a year ago. Income before income taxes and non-controlling interests was $526,000 compared to $2,947,000 a year ago. Net cash used in operating activities was $4.79 million compared to $5.38 million a year ago. Acquisition of property, plant and equipment was $1.62 million compared to $0.77 million a year ago. For the nine months, the company reported sales of $42.78 million compared to $49.58 million a year ago. Operating loss was $1,444,000 compared to operating income of $2.94 million a year ago. Income before income taxes and non-controlling interests was $1,632,000 compared to loss before income taxes and non-controlling interests of $2,480,000 a year ago. Net loss attributable to common stockholders of the company was $2,155,000, or $0.04 per basic and diluted share, compared to $1,620,000 or $0.03 per basic and diluted share a year ago. Net cash used in operating activities was $16.15 million compared to $14.68 million a year ago. Acquisition of property, plant and equipment was $7.31 million compared to $3.44 million a year ago.

Sinovac Biotech Ltd. to Report Q3, 2014 Results on Nov 14, 2014

Sinovac Biotech Ltd. announced that they will report Q3, 2014 results at 5:00 PM, China Standard Time on Nov 14, 2014

Sinovac Biotech Ltd., Q3 2014 Earnings Call, Nov 17, 2014

Sinovac Biotech Ltd., Q3 2014 Earnings Call, Nov 17, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SVA:US $5.11 USD +0.16

SVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GlaxoSmithKline PLC 1,385 GBp 0.00
Hualan Biological Engineering Inc CNY34.35 CNY +0.34
View Industry Companies
 

Industry Analysis

SVA

Industry Average

Valuation SVA Industry Range
Price/Earnings 77.7x
Price/Sales 4.3x
Price/Book 2.3x
Price/Cash Flow 77.4x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SINOVAC BIOTECH LTD, please visit www.sinovac.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.